In the larger SELECT trial in 2023, patients with heart failure, atherosclerotic disease, and overweight or obesity, treated with semaglutide 2.4 mg showed reduction in major adverse cardiac events (MACE) and heart failure end points regardless of heart failure subgroup being HFrEF or HFpEF [56,57,58]
First, all three approved sites are effective, but the abdomen is generally the easiest and most consistent
Konturek PC, Brzozowski T, Burnat G, et al
504510, Feb
With 24/7 Support Medvi Pros 24/7 access to specialists Unlimited appointments and messaging Monthly cost includes prescription, appointments, personalized plan, and more HSA/FSAeligible Insurance may reimburse for prescriptions Cons Insurance not accepted Price $179 for your first month, then $299 per month Key Specs Accepts insurance: No, but reimbursable and HSA/FSA-eligible Weight loss program included: Yes GLP-1 brand names offered: Wegovy, Zepbound Type of GLP-1 available: Injectable and oral Cancel any time: Yes Taking a new medication can be intimidating
Dual- and triple-receptor agonists also offer the potential for the treatment of obesity (3941)
